Replies to post #4143 on RespireRx Pharmaceuticals Inc (fka RSPI)

[moosedogger]

gfp- Stoll gave the answer to Ombow:

If we do need to do another financing it would be later in the year and hopefully at a far better stock price.

http://www.investorshub.com/boards/read_msg.asp?message_id=16296362

I see zero reason to doubt him- he's clearly a straight shooter.

Have to hand it to Stoll- he's handled the last 12 months challenges extremely well so far.

cheers

[jerrydylan]

http://stockcharts.com/h-sc/ui?s=COR&p=D&b=5&g=0&id=p83564298030 looked to me like she was going to rally into the close, $1.82 or so last print , then @ 4:01 a SMALL trade @ $1.77 came in.I SAW ALOT OF SIZE ON THE BID-most of the day. Not surprising to see money flow take a wack from extremely bullish levels, it doesn't mean anything other than a large amount of stock was distributed, after a major move upward. Another day or 2 and I think the real base building will begin,IOW I think the selling is profitaking....

[neuroinv]

<<That would be the "nuclear winter" scenario, with the lead compound dead and the company broke.>>
Gfp--I can only imagine what you might have been writing had Stoll not been so positive and near-ebullient:

I have probably published more about the FDA's inconsistency and irrationality than anyone else in the world, literally. But this angst is getting a bit overdone, IMHO. Even before the electron microscopy data was in, Stoll was confident enough about the toxicity/FDA situation that he did just a small PIPE. He's not foolish enough to say he is certain the FDA will agree, but everything that can be read in and between his words tells you he is very confident. And that is not his inherent nature, Roger Stoll quite easily comes to contemplate the negative possibilities. The odds of success in the FDA deliberations are higher than they have been--or will be-- for any clinical trial Cortex has ever run.

So I will say this definitively right now--that nuclear winter scenario cited above is not going to happen. Even if the 10-20% (in my estimation) possibility of FDA noncooperation comes to pass. They will either have $11-12 million in the bank by then, or they will have $6 million plus an inlicensed compound. Along with a small ($3 million?) upfront payment on a high impact R&D agreement with a BP (which would also reduce their burn, since those expenses would be shifted to the BP) they would have enough to get CX701 into the clinic, and run a small Phase II on an inlicensed drug. Those events would also allow them to do another PIPE. I don't think the terms, after those events, would be worse than they are now. Even if CX717 were shot down, they might be better. Organon will have started its spinoff, one might hear some news about Org24448.

I am not joining the Dysphoria Express. I can live with 80-90% optimism that the FDA will give CX717 the go-ahead. In which case all nuclear season forecasts go out the window.


NeuroInvestment

[Aiming4]

Gfp - perhaps that's the major part of the rationale behind the in-licensing, i.e. if the FDA kills CX-717 then COR will obviously have to raise cash soon thereafter.

And with CX-717 dead and needing to raise cash, COR would no longer have a drug in Phase II.

With an in-licensed drug secured they would.

This actually makes a lot of sense to me now.

I've always understood the general "insurance" angle of having a non-Ampakine program to fall back on and to cover the time gap after Cortex would have out-licensed their lead molecules to BP partners, but I disagreed with the in-licensing timing

Cortex has been talking about it for a long time - I would have preferred that Cortex wait until AFTER a BP deal was signed before doing an in-licensing.

Now I see the need for the timing - although I don't think this precise need has existed for the entire time Cortex has planning for an in-licensing.

But then again, it was exactly for such an unforeseeable event as the FDA's clinical hold that an in-licensing was first considered.

There's NO QUESTION Cortex is going to do an in-licensing, and soon. I re-listened to the CC last night and I'm 100% convinced the in-licensing will happen as quickly as Cortex can get it done. 2Q was repeatedly given as the in-licensing time frame on the CC, I'd even bet it will be early 2Q.

So in a nutshell, if at all possible, Cortex will get another drug in-licensed BEFORE (this is my guess) the FDA's decision.

Then should the FDA decision be bad for CX-717, Cortex would have it's new Phase II in-licensed drug to sell to PIPE investors.

Without an in-licensed drug and with CX-717 dead, Cortex would be trying to sell a PIPE based on CX-701, which won't even be starting Phase I until the middle of this year... Aiming4.